The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.
Category: Pfizer Inc
-
Trump to Announce a Drug Pricing Deal With AstraZeneca
The move would follow a similar agreement with Pfizer. Other companies are engaged in talks with the White House that would help them avoid tariffs on their products overseas.
-
How Trump’s Online Drugstore May Affect Your Drug Costs
President Trump and top health officials announced a deal with Pfizer to try to lower Medicaid prices, and a website to help consumers buy drugs directly from manufacturers.
-
Trump Announces Pfizer Deal to Lower Some Drug Prices and Unveils TrumpRx Website
The administration said the drug company would sell many of its products to the government insurance program for lower-income Americans at prices that align with those in Europe.
-
F.D.A. Reviews Cases of Covid Vaccine Deaths
The agency plans to present accounts of deaths involving children and birth defects to an influential C.D.C. panel meeting next week.
-
Trump Weighs Crackdown on Medicines From China
Behind the scenes, major pharmaceutical companies and Trump-tied billionaires are furiously lobbying in opposite directions over proposed anti-China measures.
-
F.D.A. Official Overruled Scientists on Wide Access to Covid Shots
The agency’s staff scientists pointed out how Covid was still unpredictable and posed a threat to toddlers, but the official decided to restrict shots only to children with risk factors.
-
F.D.A. Approves Covid Shots With New Restrictions
The agency’s fall recommendations underscore the goals of Health Secretary Robert F. Kennedy Jr. to limit access to the vaccines, which he has long opposed.
-
E.U. Did Not Retain Texts Sought by Journalists on Covid Vaccine Deal
The European Union acknowledged for the first time that a top official reviewed the messages, but said it had no duty to keep them, despite intense interest.
-
Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report
But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who benefited said the improvement didn’t last.